NIH Researcher introduces possible cure for Leukemia

posted in: Medical | 0
leukemia-pcp-epcalm-jpg
EPCALM Advocate Martin Nievera, Dr. Tony Leachon, Dr. Erlyn Demerre and Dr. Daniel Fowler of NIH

 

If only we could put our cancer-fighting cells in a gym, bulk them up with weight training, and transform them into super soldiers, Oh, wait a minute, we could already do that.

Imagine extracting someone else’s cancer-fighting immune cells, soaking them in a drug with antifungal properties for the survival of the fittest, then putting them back in your body. That’s exactly what happens if you undergo allogeneic rapamycin-resistant thymus-derived lymphocyte (T-cell) transplant.

Whew, that’s a mouthful, is it not? Grab some tissue for a possible nosebleed and take a moment to understand exactly how this novel treatment is making waves as the possible cure for blood cancer.

The ultimate battle: strong immunity vs. strong cancer

Leukemia, watch out. You now have a worthy contender in the form of rapamycin-resistant T-cell therapy! Immune cells, given a much-needed “upgrade,” are promising to be as good as, if not better than, chemotherapy and radiotherapy in killing cancer cells.

“To fight strong cancer, you need a strong immune system,” said Dr. Daniel Fowler, senior investigator at the National Cancer Institute. He described the leaps and bounds he and his team has made in cancer research during a leukemia awareness talk organized by the Philippine College of Physicians and the EPCALM Adult Leukemia Foundation of the Philippines.

“We take out the (T-cells of a person’s) immune system, put it in the incubator, then add rapamycin. If a T-cell can tolerate rapamycin, then it’s strong,” Fowler explained.

11fc346See more of Stef dela Cruz’s article in PULSEPOINT Create, dated October 11, 2014:

http://create.pulsepoint.com/article/100001462?

Share on FacebookTweet about this on TwitterShare on Google+Print this pageEmail this to someone